Evolus Inc .'s (NASDAQ:EOLS) Chief Financial Officer, Sandra Beaver, has recently sold a portion of her company shares, resulting in a transaction value exceeding $30,000. This sale, as reported in a recent filing, was executed at varying prices, with the average being $12.7174 per share.
On May 10, 2024, Beaver sold 2,423 shares of common stock in a series of transactions. The prices at which the shares were sold ranged from $12.51 to $13.06, with the weighted average sale price reported to be $12.7174. Following this sale, Beaver's direct ownership in Evolus stands at 151,778 shares.
The filing notes that the sale was not a discretionary trade by Beaver. Instead, it was a necessary step to cover tax withholding obligations connected to the vesting of restricted stock units. The shares were sold automatically in a "sell to cover" transaction, which is a common method for executives to satisfy tax liabilities resulting from the vesting of equity awards.
Investors and shareholders of Evolus Inc. can request detailed information about the specific number of shares sold at each price point, as Beaver has undertaken to provide full transaction details upon request to the SEC staff, the issuer, or a security holder of the issuer.
Evolus, based in Newport Beach, California, operates within the pharmaceutical preparations industry and is known for its specialized focus in life sciences.
InvestingPro Insights
Evolus Inc. (NASDAQ:EOLS) has been attracting attention not only for insider transactions but also for its financial metrics and analysts' perspectives. According to real-time data from InvestingPro, the company's market capitalization stands at $799.54 million. Despite the insider sale, Evolus shows a robust revenue growth, recording a 40.45% increase in revenue over the last twelve months as of Q1 2024, with a quarterly revenue growth of 42.21% for Q1 2024.
While the company's P/E Ratio is currently negative at -12.23, reflecting its lack of profitability over the last twelve months, the InvestingPro Tips indicate that analysts have revised their earnings upwards for the upcoming period. This could suggest a positive outlook for the company's future earnings potential. Additionally, the company's liquid assets exceed its short-term obligations, which may provide some financial flexibility in its operations.
Evolus is trading at a high Price/Book multiple of 43.35, which is often indicative of investor optimism about future growth. This is corroborated by the large price uptick over the last six months, with the company's stock price total return reaching 43.32%. Nevertheless, it's important to note that analysts do not anticipate the company to be profitable this year, and Evolus does not pay a dividend to shareholders.
For investors seeking a more comprehensive analysis, there are additional InvestingPro Tips available, which can provide deeper insights into Evolus's financial health and market performance. Interested readers can access these tips and benefit from a special offer by using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at https://www.investing.com/pro/EOLS. With a total of 7 additional InvestingPro Tips listed, subscribers can gain a more nuanced understanding of the company's prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.